





PANORAMIC Platform Adaptive trial of NOvel antiviRals for eArly treatMent of COVID-19 In the Community

panoramic@phc.ox.ac.uk Tel: 0808 156 0017

www.panoramictrial.org

REC: 21/SC/0393

EudraCT: 2021-005748-3 IRAS: 1004274

CI: Professor Chris Butler

PANORAMIC FORTNIGHTLY NEWSLETTER - ISSUE No.10, 27 February 2023



Trial Documents & Information

Useful documents and information are on the PANORAMIC website: https://www.panoramictrial.org/

The **Newsletter** is under the Healthcare Professionals tab. Documents section, if you would like to share it with colleagues.

Thank you for your continuing support!

IMP – Late Delivery

- . If IMP delivery is 1 or 2 days late and the participant is still experiencing symptoms, they can start IMP.
- The 5-day recruitment window from symptom onset applies only to the inclusion/exclusion criteria for registration and randomization. (Symptom onset does not apply to IMP start.)
- When randomizing, please advise participants to call the main central PANORAMIC line not the safety line to report IMP delivery delay. (Main phone line: 0808-156-0017)

Responding to Monitoring Queries

- Please keep an eye out for queries which are being raised by • the central data team.
- Queries will be assigned by hub/site to the PI.
- Please answer all queries as soon as possible. •

Paxlovid Administration and Dose

- Paxlovid consists of 2 medicines Nirmatrelvir and Ritonavir.
- These are co-packaged as shown in the image below.
- 2 pink tablets of Nirmatrelvir (150mg each) with 1 white tablet of Ritonavir (100mg) by mouth twice a day for 5 days.





Virology Sub-Study

VSS will be switching to cohort 1 – Intensive, until further notice.

Participant Expectations

Please explain to potential participants directed to the PANORAMIC website that there is an equal chance of being randomised to

either

IMP trial arm

or Usual Care trial arm There is no guarantee they will receive trial medication.

🖈 Taking Verbal Consent 🖈

Signatures:

 During the informed consent process, please ensure the participant name and trial team member name are entered in the correct areas on the consent form.

Participant Confirmation;

· Please inform participants who will receive their consent form via email that it is important they click the link in the email to confirm consent.



Quick Reminders



- Working Instructions Updates Day 4 and 10 safety calls WIs have been updated.
 - Please complete GP No Contact forms as soon as you can. (These are sent when the trial team have been unable to contact a participant.) The forms provide important Information for the trial.

NIHR National Institute for Health and Care Research

PANORAMIC Newsletter Issue10 V1. 27FEB2023

NHS NHS England



